This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Murphy S, Peterson P, Iland H, Laszlo J . Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.
Tefferi A, Fonseca R, Pereira DL, Hoagland HC . A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001; 76: 22–28.
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Green A, Campbell P, Buck G, Wheatley K, East C, Bareford D et al. The Medical Research Council PT1 Trial in Essential Thrombocythemia. Blood 2004; 104: 6A.
Bolanos-Meade J, Lopez-Arvizu C, Cobos E . Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia. Eur J Haematol 2002; 68: 397–399.
Sato N, Furukawa T, Masuko M, Hashimoto S, Takahashi H, Baba M et al. Acute promyelocytic leukemia developing in untreated essential thrombocythemia. Am J Hematol 2002; 71: 114–116.
Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 2004; 36: 1159–1161.
Geller SA, Shapiro E . Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982; 77: 353–356.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martin, S., DellaValla, J. Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant. Leukemia 19, 1095–1096 (2005). https://doi.org/10.1038/sj.leu.2403725
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403725
This article is cited by
-
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status
International Journal of Hematology (2014)
-
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia
International Journal of Hematology (2010)